- Home
- ESTA vs PCRX Comparison
ESTA vs PCRX Comparison
Compare ESTA & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESTA
- PCRX
- Stock Information
- Founded
- ESTA 2004
- PCRX 2006
- Country
- ESTA Costa Rica
- PCRX United States
- Employees
- ESTA N/A
- PCRX N/A
- Industry
- ESTA Industrial Specialties
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- ESTA Health Care
- PCRX Health Care
- Exchange
- ESTA Nasdaq
- PCRX Nasdaq
- Market Cap
- ESTA 1.2B
- PCRX 1.1B
- IPO Year
- ESTA 2018
- PCRX 2011
- Fundamental
- Price
- ESTA $41.59
- PCRX $24.89
- Analyst Decision
- ESTA Buy
- PCRX Buy
- Analyst Count
- ESTA 6
- PCRX 9
- Target Price
- ESTA $59.17
- PCRX $30.67
- AVG Volume (30 Days)
- ESTA 433.2K
- PCRX 839.4K
- Earning Date
- ESTA 05-07-2025
- PCRX 05-06-2025
- Dividend Yield
- ESTA N/A
- PCRX N/A
- EPS Growth
- ESTA N/A
- PCRX N/A
- EPS
- ESTA N/A
- PCRX N/A
- Revenue
- ESTA $166,025,000.00
- PCRX $700,966,000.00
- Revenue This Year
- ESTA $27.36
- PCRX $9.37
- Revenue Next Year
- ESTA $24.61
- PCRX $11.30
- P/E Ratio
- ESTA N/A
- PCRX N/A
- Revenue Growth
- ESTA 0.53
- PCRX 3.85
- 52 Week Low
- ESTA $28.16
- PCRX $11.16
- 52 Week High
- ESTA $60.12
- PCRX $31.67
- Technical
- Relative Strength Index (RSI)
- ESTA 57.01
- PCRX 54.83
- Support Level
- ESTA $38.47
- PCRX $23.93
- Resistance Level
- ESTA $41.66
- PCRX $25.88
- Average True Range (ATR)
- ESTA 2.23
- PCRX 0.91
- MACD
- ESTA 0.03
- PCRX 0.12
- Stochastic Oscillator
- ESTA 89.22
- PCRX 73.39
About ESTA Establishment Labs Holdings Inc.
Establishment Labs Holdings Inc is a medical technology company engaged in offering medical devices and aesthetic products. It is involved in the designing, manufacturing, and marketing of silicone-filled breast and body-shaping implants. The company markets its products under Motiva implants Brand. It distributes its products to medical distributors; and physicians, hospitals, and clinics in the form of direct sales. Its geographical segments are Europe, Latin America, Asia-Pacific/Middle East, and Others.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.